Biotest AG: Biotest is one of the first plasma protein manufacturers to provide digital package leaflets for all products

DGAP-News: Biotest AG

/ Key word(s): Miscellaneous

10.09.2020 / 07:00

The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest is one of the first plasma protein manufacturers to provide digital package leaflets for all products

– The latest Biotest package leaflets are always available online

– Simplified use for patients and medical professionals

– Quicker access to current safety-related information for users of Biotest products

Dreieich, 10 September 2020. Biotest is now one of the first plasma protein manufacturers to provide digital package leaflets for all products in Germany. They can be accessed both online and via an app. Even if users do not have the pack and package leaflet at hand, they can still read important information about the medication at any time and from anywhere by clicking on the app or going online.

This enables simplified use for patients and medical professionals and also ensures quicker access to current safety-related information for users of Biotest products.

Package leaflets are important. They provide users with information about medications, in particular regarding their safe and correct use. “We at Biotest felt it was vital to be able to provide our users with up-to-date versions of our package leaflets,” said Dr Claudia-Carolin Keil, Senior Director Labelling/ Corporate Regulatory Affairs. Up-to-date means that the texts are published accordingly as soon as they are approved by regulatory authorities – and this can be done much quicker than implementation in the packs for the market.

To satisfy the highest possible safety requirements, Biotest has now become a partner in the German project “Gebrauchsinformation 4.0” (“GI 4.0” – “Package Leaflet 4.0”). The GI 4.0 project, which is provided by Rote Liste Service GmbH, is a Europe-wide, unique consortium involving industry, authorities, associations and patients. ROTE LISTE Service GmbH is a subsidiary of the Federal Association of the Pharmaceutical Industry (BPI) and the Association of Research-Based Pharmaceutical Companies (vfa), as well as being publisher of the media services ROTE LISTE(R), FachInfo-Service(R), PatientenInfo-Service and Gebrauchsinformation 4.0.

The package leaflets can be accessed at https://www.gebrauchsinformation4-0.de/.

The GI 4.0 project is Germany’s way of implementing Europe’s efforts to make electronic product information (“ePI”) available. If this project is implemented by other countries or even at a European level, Biotest will also be able to publish digital package leaflets for this in an instant.

Furthermore, all of our package leaflets for blind and partially sighted users are available in a correspondingly prepared and accessible format for our patients at https://www.patienteninfo-service.de/.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.


10.09.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 – 8 01-0
Fax: 0 61 03 – 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1129381

 
End of News DGAP News Service

show this